We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Reduced PSA Screening May Delay Treatment for Earlier Onset Prostate Cancers

By LabMedica International staff writers
Posted on 13 Jan 2016
The recommendation against regular prostate specific antigen (PSA) screening for prostate cancer (PCa) has been in place for 2.5 years. More...
The number of prostate needle biopsies (PNB) has been reduced and patients who do undergo PNB are significantly more likely to be diagnosed with high risk disease, suggesting that over-diagnosis and overtreatment may have been reduced.

However, detection of intermediate-risk, potentially curable PCa has likely also decreased and there is concern that diagnosis of these treatable cancers are being delayed, according to new study, which compared the results of patients who underwent PNB before and after the recommendation to reduce PSA screening.

Deaths from PCa have declined by about 40% since the advent of PSA screening (late 1980s), and 40%–70% of that decline may be attributable to screening. However, radiation therapy and surgery have negative impacts on quality of life. The uncertain benefit of PSA-based screening, combined with the complications associated with treatment, led the US Preventive Services Task Force (USPSTF) to conclude in October 2011 that the harms of PSA-based screening outweighed the benefits, leading to their recommendation against regular screening.

"Results from our study support the argument that declining PSA screening may result in delayed diagnosis, potentially leading to avoidable cancer deaths," according to John M. Corman, MD, who led the study by researchers at Virginia Mason Medical Center (Seattle, WA, USA), "When compared to patients who underwent PNB in the 30 months prior to the USPSTF recommendation, those who underwent PNB in the 30 months after had a 33% higher relative risk of being diagnosed with high risk PCa. The reduction in the number of potentially unnecessary biopsies appears to have occurred at the cost of detecting fewer intermediate risk PCa tumors. Thus, the key concern is not only the increased risk of being diagnosed with high risk disease, but, more importantly, the missed opportunity to offer curative intervention for patients with intermediate risk PCa."

"The importance of our study is not only the evolution in patient and tumor characteristics seen at PNB, but the rapidity by which statistically significant changes occurred following the release of the USPSTF recommendations," explained Dr. Corman, "The goal of PCa screening is to maximize the benefit of screening tools such as PSA while minimizing the harm associated with over diagnosis and overtreatment. Rather than relegating PSA into oblivion, the balanced answer may be best found in the more intelligent use of available tools, implementation of shared decision-making as recommended by the American Cancer Society, and development of more effective screening techniques."

The study, by Banerji JL, Wolff EM et al., was published January 2016 issue of the Journal of Urology.

Related Links:

Virginia Mason Medical Center



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Modular Hemostasis Automation Solution
CN Track
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.